Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITDAEPS (Basic)EPS (Weighted Average and Diluted)Interest & Investment IncomeInterest ExpensesInterest ExpensesNon Operating IncomeOperating ExpensesOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Achieve Life Sciences (ACHV) Research & Development (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Research & Development for 17 consecutive years, with $3.0 million as the latest value for Q1 2026.

  • Quarterly Research & Development fell 58.08% to $3.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.8 million through Mar 2026, down 30.51% year-over-year, with the annual reading at $23.0 million for FY2025, 0.64% up from the prior year.
  • Research & Development for Q1 2026 was $3.0 million at Achieve Life Sciences, down from $3.8 million in the prior quarter.
  • The five-year high for Research & Development was $9.9 million in Q3 2022, with the low at $2.1 million in Q4 2023.
  • Average Research & Development over 5 years is $5.6 million, with a median of $5.3 million recorded in 2025.
  • The sharpest move saw Research & Development plummeted 75.46% in 2023, then surged 245.13% in 2024.
  • Achieve Life Sciences' Research & Development stood at $8.6 million in 2022, then plummeted by 75.46% to $2.1 million in 2023, then surged by 245.13% to $7.3 million in 2024, then plummeted by 47.37% to $3.8 million in 2025, then dropped by 22.53% to $3.0 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Research & Development are $3.0 million (Q1 2026), $3.8 million (Q4 2025), and $5.3 million (Q3 2025).